The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness

Journal of Psychopharmacology

Volumn 22, Issue 2 SUPPL., 2008, Pages 3-5

  Dursun, Serdar M ^a,f   Wildgust, Hiram Joseph ^b   Strickland, Paul ^a   Guy M Goodwin, ^c   Citrome, Leslie ^d   Lean, Mike ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Hiram Consulting   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CHEMICALLY INDUCED DISORDER; EDITORIAL; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; MENTAL DISEASE;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPERPROLACTINEMIA; MENTAL DISORDERS; SEVERITY OF ILLNESS INDEX;

EID: 51149111665     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107088434     Document Type: Review

References (21)

1. This editorial paper refers to papers in the supplement, Hyperprolactinaemia in schizophrenia and bipolar disorder: Clinical Implications (2008) Supplement to the Journal of Psychopharmacology volume 22. Additional references that support this editorial are given below.
2. Beumont PJ, Gelder MG, Friesen HG, Harris G, Mackinnon P, Mandelbrote BM, Wiles JM (1974) The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. Brit J Psychiatry 124: 413-419
3. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones P (2007) Minimising metabolic and cardiovascular risk in schizophrenia: 10.1177/0269881106075509
4. Brown S, Inskip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia. The Brit J Psychiatry 177: 212-217
5. Bushe C, Shaw M (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 21: 768-773
6. Dalton SO, Mellemkjaer L, Thomassen L, Mortensen PB, Johansen C (2005) Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993. Schizophr Res 75: 315-324
7. Disability Rights Commission Report (2006). Equal treatment closing the gap.
8. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M (2007) Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 90: 147-161
9. Klibanski A, Neer R. Beitins, Ridgeway C, Zervas N, McArthur (1980) Decreased bone density in hyperprolactinaemia women. New Engl J Med 303: 1511-1514
10. Kockott G, Pfeiffer W (1996) Sexual disorders in nonacute psychiatric outpatients. Comp Psychiatry 37: 56-61
11. Meltzer HY, Sachar EJ, Frantz AG (1974) Serum prolactin levels in newly admitted psychiatric patients. Neuropsychopharmacology of monoamines and their regulatory enzymes. Raven Press, New York
12. Osborn DJP, Levy G, Nazareth I, Peterson I, Islam A, King MB (2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database Arch Gen Psychiatry 64: 242-249
13. Riddle O, Bates RW, Dykshorn SW (1933) The preparation, identification and assay of prolactin - a hormone of the anterior pituitary. Am J Physiol 105: 191-216
14. Smith S, O'Keane V, Murray R (2002) Sexual dysfunction in patients taking conventional antipsychotic medication. Brit J Psychiatry 181: 49-55
15. Sulman FG, Winnik HZ (1956) Hormonal effects of chlorpromazine. Lancet 270: 161-162
16. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM (2006) Atypical antipsychotics and pituitary tumours: a pharmacovigilance study. Pharmacotherapy 26: 748-758
17. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64: 6814-6819
18. Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women. Cancer Res 66: 2476-2482
19. Tworoger S, Eliassen H, Sluss P, Hankinson S (2007). A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25: 1-7
20. Wang PS, Walker AM, Tsuang MT (2002). Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59: 1147-1154
21. Weiden P, Mackell JA, McDonell D (2002) Sexual dysfunction and adherence to antipsychotic therapy in schizophrenia. Eur Neuropsychopharmacol 12(Suppl 3): 316-317